Navigation Links
Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
Date:6/2/2011

EMERYVILLE, Calif., June 2, 2011 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba (also known as MF101), to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.

The Phase 2 clinical trial was designed to evaluate the safety and efficacy of two doses of Menerba versus placebo. The trial was a randomized, double-blinded, placebo-controlled study that enrolled 217 healthy postmenopausal women reporting moderate to severe hot flashes. Further analysis of the data was performed to evaluate if the clinical efficacy of Menerba correlates with the willingness of postmenopausal women to use Menerba for the treatment of hot flashes. We found that 73% of women with >/= 50% reduction in hot flashes and 77% of women with >/= 60% reduction in hot flash frequency were willing to continue treatment after 12 weeks of therapy. In our responder analysis, women randomized to Menerba 10 grams/day were 2.3 and 2.4 fold more likely to have >/= 50% or >/= 60% reduction in all hot flashes at 12 weeks of treatment compared to placebo (OR 2.3, p=0.03 or OR 2.4, p=0.02) respectively.

"I am very encouraged by our findings, which show that postmenopausal women are willing to take a safe, non-hormonal agent, such as Menerba, if the frequency of hot flashes is reduced by 50-60%. We know that Menerba has a demonstrated level of efficacy similar to low dose estrogen preparations and is in the target range for approval by the FDA," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer. "We are eager to initiate our Phase 3 clinical tria
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... , Oct. 2, 2014 A new Insights ... entitled, " Adherence: why it,s so hard and what ... key research findings on medication adherence and lays out ... percent through new interventions by 2017. For the past ... focused on building the body of scientific knowledge available ...
(Date:10/2/2014)... , Oct. 2, 2014   Softworld, Inc. ... a new practice solely focused on the specific needs ... While Softworld has already been highly successful in ... their additional capabilities to support the quality, regulatory, and ... is now a combination of the current Biometric team ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4CVS Health Insights Report Tackles Complex Issue of Medication Adherence 2CVS Health Insights Report Tackles Complex Issue of Medication Adherence 3Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2
... SAN DIEGO, Jan. 7, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... its academic founder and member of the Board of ... week.  He was a thoughtful leader with an incredible ... was matched by his terrific wit and disarming good ...
... N.Y., Jan. 6, 2012  VirtualScopics, Inc., (NASDAQ: ... the pharmaceutical, biotechnology and medical device industries, announced today ... from the NASDAQ Stock Market indicating that the Company,s ... consecutive business days.  NASDAQ Marketplace Rule 5550(a)(2)requires a $1.00 ...
Cached Medicine Technology:VirtualScopics Announces Receipt of Notice from Nasdaq 2VirtualScopics Announces Receipt of Notice from Nasdaq 3
(Date:10/2/2014)... Brooklyn, PA (PRWEB) October 02, 2014 ... through social engineering announced today it will host a ... The webinar will reveal the final outcome of ... at DEF CON 22 in Las Vegas and explore ... evolving social engineering attacks. To register for the ...
(Date:10/2/2014)... is a distinguished bamboo product manufacturer and retailer. Plenty ... global customers in the past few years. Now, the ... All its online workers are professional and patient; they ... company has recently added a new assortment of ... marketing specialist has announced that all these brand new ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... literally -- may face an increased risk of dying in the ... over 3,000 older Americans, researchers found those who were unable to ... three times as likely to die in the next five years, ... anosmia -- the inability to distinguish odors -- was a bigger ...
(Date:10/1/2014)... Psychiatry researchers from the University of Adelaide have developed ... likelihood of a good outcome from treatment - from ... based on a range of factors, including clinical symptoms, ... biomarkers in the patient,s blood. , Speaking in the ... the University,s Head of Psychiatry , Professor ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2
... PITTSBURGH, Jan. 18 Family caregivers who had not ... nearly two weeks longer to decide to forego further ... the issues, according to researchers from the University of ... Public Health. They share their findings in a poster ...
... , AMES, Iowa -- Parents may have good reason ... have been spending playing their new video games since ... team -- including an Iowa State University psychologist -- ... and that greater amounts of gaming, lower social competence ...
... BOSTON Beth Israel Deaconess Medical Center (BIDMC) investigators Lewis ... awarded the distinction of AAAS Fellows by the American Association ... members to be recognized this year for their distinguished efforts ... AAAS Annual Meeting in February. Chief of BIDMC,s Division ...
... in particular the CAMERA study, has used MRI to study ... higher proportion of these patients exhibit lesions of the brain ... Lesions of the brain microvessels , Lesions of ... of various kinds: white-matter hyperintensities and, more rarely, silent infarcts ...
... a genetic blood test and a five-minute functional MRI ... many of whom were destined to develop cognitive decline ... John Woodard, Ph.D., associate professor of psychology in ... of Gerontology at Wayne State University, is lead author ...
... Western Reserve University School of Medicine and Athersys, Inc. ... cord injury will be published today in the January ... study, by leading researchers from the Department of Neurosciences ... presents data supporting the potential therapeutic benefit of Athersys, ...
Cached Medicine News:Health News:Pitt study: End-of-life decisions take longer if patient hasn't shared wishes with family 2Health News:New Pediatrics study identifies the risks, consequences of video game addiction 2Health News:New Pediatrics study identifies the risks, consequences of video game addiction 3Health News:Migraines and headaches present no risk to cognitive function 2Health News:Migraines and headaches present no risk to cognitive function 3Health News:Wayne State University study predicts risk of memory loss in healthy, older adults 2Health News:Case Western Reserve and Athersys show regenerative benefit of MultiStem after spinal cord injury 2Health News:Case Western Reserve and Athersys show regenerative benefit of MultiStem after spinal cord injury 3
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: